Literature DB >> 7908532

Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.

K S Channer1, M A James, T MacConnell, J R Rees.   

Abstract

1. The ideal drug treatment for atrial fibrillation will control resting heart rate, blunt exercise induced tachycardia whilst not exacerbating nocturnal bradycardia. Monotherapy with digoxin may not be ideal. We have compared the effect of combining digoxin (0.25 mg daily) with atenolol 50 mg and 100 mg or pindolol 5 mg twice daily and 15 mg twice daily in a cross-over randomised single-blind trial in eight symptomatic patients (six male; mean age 62 years) with poorly controlled atrial fibrillation. 2. Heart rate control was measured by 24 h ECG at baseline on digoxin therapy and after 2 weeks with each treatment. Symptom scores for breathlessness and palpitation were measured using visual analogue scales. 3. The addition of both beta-adrenoceptor blockers significantly reduced mean diurnal maximum heart rate from baseline (all P < 0.001 ANOVA). Atenolol at both doses caused a greater reduction than either dose of pindolol (P < 0.001 ANOVA). Nocturnal maximum heart rate was not significantly reduced from baseline by either beta-adrenoceptor blocker, but both doses of pindolol caused increases in nocturnal maximum heart rate compared with atenolol (P < 0.001 ANOVA). 4. Atenolol caused a reduction in diurnal minimum heart rate compared with baseline and caused a reduction in nocturnal minimum heart rate whereas pindolol caused an increase (P < 0.001 ANOVA). 5. Atenolol 100 mg caused longer nocturnal pauses compared with baseline but pindolol 15 mg twice daily reduced the number of nocturnal pauses > 1.5 s (P = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908532      PMCID: PMC1364709          DOI: 10.1111/j.1365-2125.1994.tb04238.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Twenty four hour ambulatory electrocardiography in patients with chronic atrial fibrillation.

Authors:  D Pitcher; M Papouchado; M A James; J R Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

2.  Improved control of atrial fibrillation with combined pindolol and digoxin therapy.

Authors:  M A James; K S Channer; M Papouchado; J R Rees
Journal:  Eur Heart J       Date:  1989-01       Impact factor: 29.983

3.  Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.

Authors:  A O Molajo; M O Coupe; D H Bennett
Journal:  Br Heart J       Date:  1984-10

4.  Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation.

Authors:  J Yahalom; H O Klein; E Kaplinsky
Journal:  Chest       Date:  1977-05       Impact factor: 9.410

5.  Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation.

Authors:  R Beasley; D A Smith; D J McHaffie
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

6.  Towards improved control of atrial fibrillation.

Authors:  K S Channer; M Papouchado; M A James; D W Pitcher; J R Rees
Journal:  Eur Heart J       Date:  1987-02       Impact factor: 29.983

7.  Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.

Authors:  R DiBianco; J Morganroth; J A Freitag; J A Ronan; K M Lindgren; D J Donohue; L J Larca; K D Chadda; A Y Olukotun
Journal:  Am Heart J       Date:  1984-10       Impact factor: 4.749

8.  Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation.

Authors:  J E Atwood; M Sullivan; S Forbes; J Myers; W Pewen; H G Olson; V F Froelicher
Journal:  J Am Coll Cardiol       Date:  1987-08       Impact factor: 24.094

9.  Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.

Authors:  D David; E D Segni; H O Klein; E Kaplinsky
Journal:  Am J Cardiol       Date:  1979-12       Impact factor: 2.778

10.  Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.

Authors:  E L Ang; W L Chan; J G Cleland; D Moore; S J Krikler; N D Alexander; C M Oakley
Journal:  Br Heart J       Date:  1990-10
  10 in total
  7 in total

Review 1.  Current management of symptomatic atrial fibrillation.

Authors:  K S Channer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.

Authors:  A Herxheimer
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

Review 3.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

4.  Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.

Authors:  Shirin S Joseph; James A Lynham; Peter Molenaar; Andrew A Grace; William H Colledge; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-08       Impact factor: 3.000

Review 5.  New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

Authors:  Stanley Nattel; Paul Khairy; Denis Roy; Bernard Thibault; Peter Guerra; Mario Talajic; Marc Dubuc
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial.

Authors:  William T Abraham; Jonathan P Piccini; Christopher Dufton; Ian A Carroll; Jeffrey S Healey; Christopher M O'Connor; Debra Marshall; Ryan Aleong; Dirk J van Veldhuisen; Michiel Rienstra; Stephen B Wilton; Michel White; William H Sauer; Inder S Anand; Sophia P Huebler; Stuart J Connolly; Michael R Bristow
Journal:  Heart Rhythm O2       Date:  2021-11-14

7.  A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics.

Authors:  Radda Rusinova; Roger E Koeppe; Olaf S Andersen
Journal:  J Gen Physiol       Date:  2015-11-16       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.